Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Real-world safety and efficacy of belantamab mafodotin in R/R multiple myeloma

In this video, Yael Cohen, MD, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, shares some key findings from a real-world study evaluating the safety and efficacy of belantamab mafodotin in patients with relapsed/refractory (R/R) myeloma. Dr Cohen highlights the overall response rate (ORR) and progression-free survival (PFS) observed, and the value of this real-world data. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.